Edesa Biotech is trading at $2.52, up 10.53% versus its November 3 regular-session close of $2.28; no verified November 3 company-specific catalyst was identified. - Recent coverage points to the FDA’s October 15 clearance for its Phase 2 vitiligo study, not a new after-hours event. - The supplied market context is mixed and does not establish a broader-market cause; after-hours volume or activity details were not provided.